IDXX · Q2 2025 Earnings
BullishIdexx Laboratories
Reported August 4, 2025
30-second summary
30-second take: Idexx delivered Q2 revenue of $1.11B (+10.6% YoY) and non-GAAP EPS of $3.50, with CAG Diagnostics recurring revenue organic growth of 7.4% and a quarterly-record ~2,400 inVue Dx placements driving a 13.6% organic jump in VetLab consumables. Management raised the FY2025 revenue, EPS, and inVue Dx placement guides — the placement target moves from 4,500 to 5,500 units with instrument revenue now expected above $60M. The signal: U.S. clinical visits remain down 2.5%, but diagnostic frequency expansion and instrument-led recurring revenue are widening the premium-to-visits gap (now ~800bps), and management is investing into the strength rather than hunkering down.
Headline numbers
EPS
Q2 FY2025
$3.50
Revenue
Q2 FY2025
$1.11B
+10.6% YoY
Gross margin
Q2 FY2025
62.6%
Free cash flow
Q2 FY2025
$0.15B
Operating margin
Q2 FY2025
33.6%
Key financials
Q2 FY2025| Metric | Q2 FY2025 | YoY |
|---|---|---|
| Revenue | $1.11B | +10.6% |
| EPS | $3.50 | — |
| Gross margin | 62.6% | — |
| Operating margin | 33.6% | — |
| Free cash flow | $0.15B | — |
Guidance
Prior quarter data unavailable — comparison not possible.
Segment KPIs
Q2 FY2025| Segment | Q2 FY2025 | YoY |
|---|---|---|
| Companion Animal Group (CAG) | $1.022B | +10.9% |
| Water | $0.051B | +9.1% |
| Livestock, Poultry and Dairy (LPD) | $0.032B | +4.8% |
| CAG Diagnostics Recurring Revenue | $0.878B | +8.6% |
| IDEXX VetLab Consumables | $0.375B | +15.3% |
| Reference Laboratory Diagnostic and Consulting Services | $0.368B | +5.9% |
| CAG Diagnostics Capital - Instruments | $0.059B | +66.0% |
| Veterinary Software, Services and Diagnostic Imaging Systems | $0.086B | +9.3% |
Other KPIs
Q2 FY2025| Segment | Q2 FY2025 |
|---|---|
| CAG Diagnostics Recurring Revenue Organic Growth | 7% |
| IDEXX VetLab Consumables Organic Growth | 13.6% |
| CAG Diagnostics Capital Instrument Placements (inVue Dx) | ~2,400 placements (quarterly record) |
| Global Premium Instrument Installed Base Growth | 10% |
| Gross Margin | 62.6% |
| Operating Margin | 33.6% |
| Free Cash Flow Conversion (Net Income to FCF) | ~82% (Q2 run-rate) |
| Comparable EPS Growth | 17% |
Management tone
Management is unusually forward-leaning for a diagnostics franchise operating into a -2.5% U.S. clinical visit backdrop. Five specific shifts:
Clinical visit declines have been reframed from constraint to backdrop. Where the natural narrative would treat -2.5% U.S. visits as a drag to manage around, management now treats it as the constant against which the diagnostic-frequency story plays out: "Diagnostic frequency and utilization per clinical visit continued to expand solidly at the clinic level, highlighting the important and expanding role of diagnostics for those seeking veterinary services." This shifts the bull case from "wait for visits to recover" to "visits don't need to recover for the model to compound."
inVue Dx has graduated from "new product ramp" to "transformational platform." Six months into commercial scale, management raised the FY placement target by 1,000 units — from 4,500 to 5,500 — mid-year: "Demand has exceeded expectations. We have now placed nearly 2,700 instruments globally this year through June giving us confidence to increase our 2025 placement estimate by 1,000 units from 4,500 to 5,500." A 22% mid-year raise on a flagship platform is rare and signals management believes they were demand-constrained, not supply-constrained, in the original plan.
CancerDx is now framed as a reference lab volume multiplier, not a product line. With 2,500+ practices ordering and ~15% of sample submissions coming from competitive lab customers, the international rollout in 2026 is being teed up as a share-take vehicle: "As awareness grows and we broaden the testing menu over time to incorporate new cancer types, we expect a multiplier to our reference lab testing volumes."
Commercial investment is going up, not down. Three additional country organizations and modest U.S. sales force expansion are being layered on into the back half: "These high return investments are a reflection of the confidence we have in growing these geographies and supporting a broader portfolio of diagnostic products that are resonating strongly with customers." Adding headcount when the U.S. visit environment is still negative is a confidence tell.
Macro language is calmer. "While macroeconomic pressures persist in many of our key regions, veterinary practices continue to prioritize investments in diagnostics and software" — the framing has moved from sector-headwind monitoring to durability of demand, with the pet healthcare market positioned as resilient rather than under pressure.
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
Chris Schott · JP Morgan
Elaboration on in-view uptake and practice types experiencing traction; clarification on 5,500 placement forecast implying slowdown from Q2 and any gating factors for rest of year
Customer feedback on in-view is excellent, driven by workflow benefits and consistent results for ear cytology and blood morphology. 5,500 placement forecast is reasonable based on tracked consumables usage. FNA lumps and bumps launch later in year will drive further interest. Placements span existing IDEX customers and new prospects; mix of suites with and without chemistry/hematology solutions.
Erin Wright · Morgan Stanley
Details on consumables agreements tied to placements; consumables utilization surprises; corporate vs. independent practice uptake pace; breakdown of consumables growth contribution from InView vs. other products
Management doesn't break out InView consumables separately from other tests. MVDX has paper-run and auto-replenishment capability. Independent practices move faster than corporate (which pilot extensively first). Consumables usage aligns with expectations; ear cytology and blood morphology are common daily and frequent use cases. Cortisol test launched last week. Overall consumables organic growth was strongest in two years with multiple contributors.
Michael Riskin · Bank of America
Revenue guidance bridge analysis ($90M increase: $70M FX, $20M operational with $10M from InView placements); clarification on initial consumables bolus and ramp-up timing post-placement
$70M FX-related, $20M operational growth. InView placements increased from $50M to $60M (5,500 vs. previous guidance). No typical large bolus of consumables at launch; paper-run auto-replenishment tracks usage and triggers shipments. Company has improved onboarding/training to avoid long ramp periods. Three additional country expansions and modest U.S. sales force expansion support operational growth despite 2.5% clinical visit headwind.
John Block · Stifel
Q2 intra-quarter trends; CAG DX recurring revenue divergence between international (strong) and U.S. (mid-single digit growth); InView premium reacceleration in 2Q vs. back-half guidance
No material intra-quarter trends identified; Q1 had 600 InView placements, broadly tracking expectations. International CAG DX recurring revenue strong; U.S. mid-single digit growth with recent improvement (150+ bps vs. Q1 on days-adjusted basis). Diagnostic frequency up 50 bps in Q2. U.S. product launches start here before international rollout; international markets show rapid uptake of specialty tests (pancreatic lipase, cortisol) due to DVM sales infrastructure. Second half implied 9% organic growth at midpoint vs. 7.4% CAG DX recurring in Q2.
David Westenberg · Piper Sandler
International market growth decomposition between market growth, share gains, and utilization; tariff-related pull-forward impact in Q2 on consumables
International opportunity more embryonic than U.S. (blood work inclusion ~1/3 of U.S. levels). Growth driven by customer support, diagnostic utilization expansion, and point-of-care fit for small independent clinics. Product-market fit strong (ProSite 1 economical at lower usage). Infrastructure of commercial, reference labs, and software tools (VetConnect Plus) enables growth. No meaningful tariff-related customer order pattern changes observed; paper-run model mitigates pull-forward risk on consumables side.
What to watch into next quarter
Whether inVue Dx placement cadence holds. Q1 ran ~600 units, Q2 jumped to ~2,400. To hit 5,500 for FY, 2H needs ~2,500 combined. Watch for any commentary on backlog vs. run-rate placements in Q3.
U.S. CAG Diagnostics recurring revenue growth re-acceleration. Days-adjusted improvement of 150+bps vs. Q1 is encouraging; watch whether U.S. organic recurring exits 2025 above 6% with clinical visits still negative — that's the proof point for the frequency-expansion thesis.
Q3 comparable operating margin direction. Management guided to "modest" comparable expansion in Q3 as commercial investments hit; watch whether FY comparable margin lands in the upper half of the +50–80bps band or compresses toward the low end as the three country expansions ramp.
CancerDx pull-through to reference lab volumes. With 2,500+ practices ordering and ~15% of submissions coming from competitive labs, watch whether reference lab services growth (5.9% in Q2) accelerates in 2H as the test menu broadens.
VetLab consumables organic growth sustainability. +13.6% is a two-year high. Watch whether 2H prints sustain double digits — if it slips back to high single digits, the inVue-led narrative weakens.
Sources
- IDXX Q2 2025 press release, SEC filing (Form 8-K Exhibit 99.1): https://www.sec.gov/Archives/edgar/data/874716/000110465925073304/tm2522386d1_ex99-1.htm
- IDXX Q2 2025 earnings conference call (Q&A and prepared remarks excerpts as captured in extraction)
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.